Natriumvalproaat Sandoz (Sodium Valproate)

Sodium Valproate, the active ingredient in Natriumvalproaat Sandoz, is an anticonvulsant presented as an oral formulation for oral use. It is employed to control generalized and focal seizures, stabilize mood in bipolar disorder, and prevent migraine attacks in adult patients.

GNH USA supplies Natriumvalproaat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand through reliable logistics and dedicated customer support.

Natriumvalproaat Sandoz is used in the management of seizure disorders and related neurological conditions.

Epilepsy (generalized and focal seizures): reduces seizure frequency and severity in adult and pediatric patients. Bipolar disorder (mood stabilization): helps maintain mood stability and prevents manic or depressive episodes. Migraine prophylaxis: decreases the number of migraine attacks and lessens headache intensity.

Sodium valproate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Tremor - Weight gain - Drowsiness

Serious or Rare Side Effects: - Liver toxicity (hepatitis, elevated transaminases) - Pancreatitis - Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)

When prescribing Natriumvalproaat Sandoz, clinicians should observe several safety precautions to minimise risk. - Liver function monitoring: obtain baseline tests and repeat periodically during therapy. - Blood count surveillance: check platelet levels regularly to detect thrombocytopenia. - Pregnancy avoidance: drug is contraindicated in pregnancy due to high teratogenic risk (Category X). - Mitochondrial disorder caution: avoid use in patients with known mitochondrial disease or urea cycle disorders. - Concomitant medication review: assess for drugs that may alter valproate levels or increase toxicity. - Store at room temperature: keep in original packaging, protect from moisture and excessive heat.

Sodium valproate interacts with several medicines; some combinations require avoidance while others need careful monitoring.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, markedly reducing valproate plasma concentrations. - Phenytoin: accelerates valproate clearance, compromising seizure control. - Rifampin: strong enzyme inducer that lowers valproate levels and efficacy.

Moderate Interactions (Monitor Closely): - Aspirin: may increase risk of bleeding by affecting platelet function. - Lamotrigine: combined use can raise risk of serious skin reactions, requiring dose adjustments.